Turquoise, the UK merchant bank specialising in energy, environment and efficiency, has invested in Ablatus Therapeutics for the Low Carbon Innovation Fund 2 (LCIF2). The investment of £85,000 is part of an overall round which could reach £1.5 million.

Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques, in order to offer greater clinical options and to improve patient outcomes.